Johnson & Johnson (JNJ) said the company expects fiscal 2025 adjusted EPS in a range of $10.50 - $10.70, which represents a growth of 6.2%, at midpoint. Adjusted operational EPS is estimated in a range of $10.75 - $10.95, which represents a growth of 8.7%, at midpoint. Johnson & Johnson noted that its guidance excludes impact from the recently announced acquisition of Intra-Cellular Therapies Inc. The anticipated impact from planned ITCI acquisition is in a range of $0.30 - $0.35 to 2025 adjusted earnings results. Analysts on average expect the company to report profit per share of $10.60. Analysts' estimates typically exclude special items.
For fiscal 2025, the company expects reported sales in a range of $89.2 billion - $90.0 billion. Operational sales are estimated in a range of $90.9 billion - $91.7 billion. Adjusted operational sales are projected to rise 2.5%, at mid-point of guidance range.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.